MyoKardia, Inc. - Common Stock MYOK announces its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.
Earnings and Revenue
Based on management's projections, MyoKardia analysts modeled for a loss of 41 cents per share on sales of $6.08 million.
If the company were to post earnings inline with the consensus estimate when it reports Thursday, EPS would be up 24.24 percent. Sales would be up 71.27 percent from the year-ago period.
Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
| EPS Estimate | -0.41 | -0.37 | -0.31 | -0.18 |
| EPS Actual | -0.42 | -0.41 | -0.37 | -0.33 |
Stock Performance
Over the last 52-week period, shares are up 358.1 percent. Given that these returns are generally positive, long-term shareholders should be content going into this earnings release.
Analyst estimates are adjusted lower for EPS and revenues over the past 90 days. The popular rating by analysts on MyoKardia stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
MyoKardia's conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
